GSK reported second-quarter financial results on July 28, with total turnover rising 5% at constant exchange rates to £8.4 billion, while core operating profit climbed 7% to £2.80 billion and core EPS rose 9% to 50.5p. Total operating profit dropped 75% to £481 million after a £1.3 billion non-cash impairment charge tied to discontinuing camlipixant following Phase III trial results. Management announced it now expects more than 20 Phase III trial starts in 2026, up from a prior projection of 10, and launched a three-year 'Accelerate Growth' restructuring program aimed at generating £1.9 billion in annual cost savings by 2029 at a total cost of £2.4 billion. ViiV Healthcare, GSK's majority-owned HIV business, presented positive Phase IIIb VOGUE study data supporting its long-acting HIV regimen portfolio.
GSK plcQ2 results beat with core EPS up 9%, plus accelerated pipeline and cost savings program
Positive Phase IIIb VOGUE data supports long-acting HIV regimen portfolio
